Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other proliferative diseases. Established in 1992 and headquartered in Berkeley Heights, New Jersey, the company specializes in oral treatments that influence various phases of cell cycle control. Its oncology pipeline features several promising candidates, including CYC065, a cyclin-dependent kinase (CDK) inhibitor currently undergoing Phase I trials for solid tumors and chronic lymphocytic leukemia, and CYC140, a polo-like kinase (PLK) inhibitor in Phase I trials for advanced leukemias. Additionally, Cyclacel is advancing sapacitabine, an oral nucleoside analogue, in combination studies for patients with BRCA mutations, along with ongoing Phase III trials for acute myeloid leukemia. The company collaborates with the University of Texas MD Anderson Cancer Center to assess the safety and efficacy of its treatments in hematological malignancies and has partnered with ManRos Therapeutics for the development of oral seliciclib capsules aimed at treating cystic fibrosis.